

Notice of Special Interest (NOSI):

Research to Improve Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment NOT-CA-19-059

Healthcare Delivery Research Program (HDRP)


Division of Cancer Control & Population Sciences (DCCPS)

November 12, 2019



<https://healthcaredelivery.cancer.gov/>

Using WebEx and Webinar Logistics



- All lines will be in listen-only mode
- Submit questions at any time using the Q&A or Chat Panel and select *All Panelists*
- You may need to activate the appropriate box using the floating navigation panel. Found on the center of your screen



- This webinar is being recorded

Webinar presenters

Sallie J. Weaver, PhD, MHS
Health Systems & Interventions Research Branch
Healthcare Delivery Research Program
Division of Cancer Control & Population Sciences NCI
sallie.weaver@nih.gov



Veronica Chollette, RN, MS
Health Systems & Interventions Research Branch
Healthcare Delivery Research Program
Division of Cancer Control & Population Sciences NCI
cholletv@mail.nih.gov



Overview

- Background
- Notice of Special Interest (NOSI) Details
 - What is a NOSI?
 - Goals and scope
 - Application details
 - Resources
- Questions
 - NOTE: Questions about specific aims will not be addressed

Background

NCI Healthcare Delivery Research Program

NCI DCCPS organizational structure

Division of Cancer Control and Population Sciences (DCCPS)

*Office of Cancer Survivorship
Implementation Science*

**Healthcare
Delivery
Research
Program (HDRP)**


**Behavioral
Research
Program (BRP)**

**Epidemiology
and Genomics
Research
Program (EGRP)**

**Surveillance
Research
Program (SRP)**

Healthcare Delivery Research Program (HDRP)

Advancing innovative research to improve the delivery of cancer-related care



<https://healthcaredelivery.cancer.gov>

Background

*Research to Improve Interprofessional Teamwork and Coordination
During Cancer Diagnosis and Treatment
NOT-CA-19-059*

Suboptimal coordination during cancer treatment is a public health problem

- **Common:** Significant proportion of cancer patients experience treatment coordination issues
- **Costly:** Poor coordination affects costs, workload, adherence, outcomes, medical errors
- **Complex:** Increasing range of disciplines, settings engaged
 - Lung, GI, breast, male & female reproductive cancers: 14 to 17 clinicians
 - Coordination challenges amplified for underserved populations in community settings
- Unclear which team characteristics and teamwork processes produce better care quality, patient outcomes, utilization

Notice of Special Interest (NOSI) Details

*Research to Improve Interprofessional Teamwork and Coordination
During Cancer Diagnosis and Treatment
NOT-CA-19-059*

What is a notice of special interest (NOSI)?

- Notice posted in the NIH guide that institutes and centers can use to share, update research priorities
- Points to funding opportunity announcements (FOAs) through which investigators can apply
 - Usually NIH or DCCPS parent announcements
 - Standing study sections, no set-aside \$
- Before 2019: Used by some NIH institutes and centers
- 2019 and beyond: NOSI will replace non-parent Program Announcements (PA)

NOT-CA-19-059: Goal

Highlight interest in receiving investigator-initiated grant applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment

Focus: Research that...

- Identifies effective strategies for improving performance of interprofessional cancer care teams during cancer diagnosis and treatment
- Addresses care coordination challenges:
 - Within and/or between care settings (e.g., between tertiary care and community settings)

Areas of scientific interest for this NOSI

Research encouraged through this Notice includes, but is not limited to, studies that:

- Identify modifiable features of care team **structure** (e.g., care team composition or organization), associated with differences in cancer care quality and patient outcomes
- Identify modifiable features of care team **processes** (e.g., decision making, communication, coordination behaviors, collaboration, leadership) associated with differences in cancer care quality and patient outcomes

Areas of scientific interest for this NOSI (cont.)

- Identify characteristics at the patient, caregiver, care team, delivery organization, health system, and/or community levels that influence the functioning and effectiveness of interprofessional cancer care teams
- Develop and test interventions designed to improve cancer care quality and patient outcomes by **modifying** the structure and/or functioning of interprofessional teams
- Develop and test interventions designed to improve cancer care quality and patient outcomes by **engaging** patients and caregivers as members of their cancer care team

How do I submit an application in response to this NOSI?

- Applications for this initiative must be submitted using one of four different funding opportunity announcements (FOAs)

	FOA	First Available Due Date
R01	PAR-18-559 Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	October 5, 2019
R01	PA-19-056 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	October 5, 2019
R01	PAR-18-869 Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	November 7, 2019
P01	PAR-18-290 National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)	January 25, 2020

- FOA expiring? Applications may be submitted to any of the reissuances of these announcements through January 8, 2022

Grant mechanism: R01

NIH/DCCPS Research Project Grant (R01)

- Supports a discrete, specified research project
- No specific dollar limit
 - Advance permission required for \geq \$500K direct costs in any year, minimum of 8 weeks before targeted receipt date
- 3 to 5 year project period
- Standard due dates
- Clinical trial? Use [PAR-18-559 Cancer Prevention and Control Clinical Trials Grant Program \(R01 Clinical Trial Required\)](#)
- No clinical trial? Use [PA-19-056 NIH Research Project Grant \(Parent R01 Clinical Trial Not Allowed\)](#)

Grant mechanism: Modular R01

DCCPS Modular Research Project Grant (R01)

- Supports a discrete, specified research project
- Focus: Smaller scale studies
- Direct costs for any year may NOT exceed \$250K
- 2 to 5 year project period
- 2 due dates per year: March 2, 2020; Nov. 6, 2020; March 8, 2021
- [PAR-18-869: Modular R01s in Cancer Control and Population Sciences \(R01 Clinical Trial Optional\)](#)

Grant mechanism: P01

NCI Program Project Grant (P01)

- Supports integrated, multi-project research projects involving a number of independent investigators who share knowledge and common resources
- 3 research projects and administrative core
- Each project contributes or is directly related to the common theme of the overall programmatic research goal, thus forming a cohesive and well-defined system of research activities and projects
- Pre-submission meeting required 6 to 9 months before receipt date
- [PAR-18-290 National Cancer Institute Program Project Applications \(P01 Clinical Trial Optional\)](#)

Other NOSI considerations

- Research should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes
- Not required, but encouraged: Research focused on needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (e.g. community-based cancer centers or clinics)

Application requirements

- All instructions in the [SF424 \(R&R\) Application Guide](#) and the funding opportunity announcement used for submission must be followed
- **Applicants must include “NOT-CA-19-059” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form**
 - Applications without this information in box 4B will not be considered for this initiative
- Carefully read the entire funding opportunity announcement for which you are applying

Application requirements: Clinical trials

- NIH requirements for clinical trials research applications were updated in January 2018. Please note the following policies:
 - Application form now consolidates all Human Subjects and Clinical Trial related information into one section and also expands information required for clinical trials applications (FORMS-E)
 - Investigators and staff must receive training in Good Clinical Practice
 - All sites participating in multi-site studies research will use a single IRB
 - All NIH-funded clinical trials are expected to register and submit results to Clinicaltrials.gov
- Information about the NIH Clinical Trial Requirements:
<https://grants.nih.gov/policy/clinical-trials.htm>

Standard review criteria

Overall impact

Scored review criteria

- Significance
- Investigators
- Innovation
- Approach
- Environment

Additional review criteria

- *Study timeline (for clinical trials)
- Protections for Human Subjects
- Inclusion
- Vertebrate Animals
- Biohazards

Additional review considerations

- Check funding opportunity announcement to see resource sharing plan requirements (e.g., data sharing plan)

Important dates

- Earliest submission date: See Notice, varies based on funding announcement selected
- Application due date: See “Part 1: Key dates” of funding announcement selected
- Notice expiration date: January 8, 2022
- Start the process early
- Read the notice and eligible funding announcements very carefully
- Discuss 1-page summary with program contacts listed in Notice


Resources

- Today's webinar and FAQ will be posted on our website:
<https://healthcaresdelivery.cancer.gov/media>
- Connect with NOSI Program Contacts early

Sallie Weaver, PhD, MHS
sallie.weaver@nih.gov

Veronica Chollette, RN, MS
cholletv@mail.nih.gov

Additional resources




[Special series: NCI-ASCO Teams in Cancer Care papers. Journal of Oncology Practice. Nov 2016; 12\(11\): 955-1147.](#)

<https://healthcaredelivery.cancer.gov/healthcare/>

Questions?

Please type your questions in the Q & A section on WebEx



Sallie Weaver
sallie.weaver@nih.gov

Veronica Chollette
cholletv@nih.gov